D The present invention relates to ion pair catalysts (I) comprising the cationic bisguanidinium ligand (A) and diperoxomolybdate anion (B). The present invention also relates to ion pair catalysts (III) comprising the cationic bisguanidinium ligand (C) and peroxotungstate anion (D). It further relates to the use of the said catalysts in the manufacture of enantiomerically enriched sulfoxides. ##STR00001##

To provide a novel class-A GPCR antagonist, a production method therefor, or a novel compound that interacts with a Na.sup.+-water cluster binding site of a class-A GPCR.

Used is a compound or a salt thereof comprising a structure comprising a class-A GPCR-binding compound linked to a functional group that can bind to a Na.sup.+-water cluster binding site of the class-A GPCR. Also used is a method for producing a class-A GPCR antagonist, comprising the step of linking one compound with another compound that can bind to a Na.sup.+-water cluster binding site of the class-A GPCR.

A method for removing carbon dioxide from a gaseous source, the method comprising: (i) contacting said gaseous source with an aqueous solution of a carbon dioxide sorbent that reacts with carbon dioxide to form an aqueous-soluble carbonate or bicarbonate salt of said carbon dioxide sorbent; (ii) contacting the aqueous solution from step (i) with a bis-iminoguanidine carbon dioxide complexing compound, which is different from the carbon dioxide sorbent, to result in precipitation of a carbonate or bicarbonate salt of said carbon dioxide complexing compound and regeneration of the carbon dioxide sorbent; and (iii) removing the precipitated carbonate or bicarbonate salt from the aqueous solution in step (ii) to result in a solid form of said carbonate or bicarbonate salt of the carbon dioxide complexing compound. The method may further include a step (iv) of regenerating the carbon dioxide complexing compound by subjecting the precipitated salt to sufficient heat and/or vacuum.

A guanidine of the formula (I) and to the use thereof as catalyst for the crosslinking of a functional compound, especially a polymer having silane groups. The guanidine of the formula (I) described is preparable in a simple method via a polyfunctional carbodiimide adduct from the readily available raw materials, and is largely odorless at room temperature and of low toxicity. In spite of its comparatively high molecular weight, it accelerates the crosslinking of functional compounds surprisingly well, and such compositions do not have a tendency to migration-related defects such as separation, exudation or substrate soiling.

A guanidine of the formula (I) and to the use thereof as catalyst for the crosslinking of a functional compound, especially a polymer having silane groups. The guanidine of the formula (I) described is preparable in a simple method via a polyfunctional carbodiimide adduct from the readily available raw materials, and is largely odorless at room temperature and of low toxicity. In spite of its comparatively high molecular weight, it accelerates the crosslinking of functional compounds surprisingly well, and such compositions do not have a tendency to migration-related defects such as separation, exudation or substrate soiling.

Cycloalkylamine derivatives may be used for preventing or treating diseases in humans, animals, and have demonstrated efficacy specifically in treating type 2 diabetes. In an embodiment, the cycloalkylamine derivatives can include a compound selected from the group consisting of cycloheptanamine salts, cyclohexanamine salts, cyclopentanamine salts 1-cycloheptyl-[4,4-bipyridin]-1-ium, N1,N2-dicycloheptyloxalamide, 1-[3,5-bis(trifluoromethyl)phenyl]-3-cycloheptylurea, 1,1-(4-methyl-1,3-phenylene)bis(3-cycloheptylurea), 1-(2-aminopyrimidin-4-yl)-3-cycloheptylurea, 4-amino-N-(cycloheptylcarbamoyl)benzenesulfonamide, 4-(3-cycloheptylureido)-N-(5-methylisoxazol-3-yl)benzenesulfonamide, N-(cycloheptylcarbamoyl)-4-methylbenzenesulfonamide, 1-cycloheptylguanidine hydrochloride, (E)-amino[(amino(cycloheptylamino)methylene)amino]methaniminium chloride, or a pharmaceutically acceptable salt thereof.

Cycloalkylamine derivatives may be used for preventing or treating diseases in humans, animals, and have demonstrated efficacy specifically in treating type 2 diabetes. In an embodiment, the cycloalkylamine derivatives can include a compound selected from the group consisting of cycloheptanamine salts, cyclohexanamine salts, cyclopentanamine salts 1-cycloheptyl-[4,4-bipyridin]-1-ium, N1,N2-dicycloheptyloxalamide, 1-[3,5-bis(trifluoromethyl)phenyl]-3-cycloheptylurea, 1,1-(4-methyl-1,3-phenylene)bis(3-cycloheptylurea), 1-(2-aminopyrimidin-4-yl)-3-cycloheptylurea, 4-amino-N-(cycloheptylcarbamoyl)benzenesulfonamide, 4-(3-cycloheptylureido)-N-(5-methylisoxazol-3-yl)benzenesulfonamide, N-(cycloheptylcarbamoyl)-4-methylbenzenesulfonamide, 1-cycloheptylguanidine hydrochloride, (E)-amino[(amino(cycloheptylamino)methylene)amino]methaniminium chloride, or a pharmaceutically acceptable salt thereof.

An anti-inflammatory drug containing a G0/G1 switch 2 (G0S2) inhibitor as an active ingredient is useful as a novel anti-inflammatory drug.

An anti-inflammatory drug containing a G0/G1 switch 2 (G0S2) inhibitor as an active ingredient is useful as a novel anti-inflammatory drug.

This invention relates to compounds that inhibit creatine transport and/or creatine kinase, pharmaceutical compositions including such compounds, and methods of utilizing such compounds and compositions for the treatment of cancer.